In-Vitro Diagnostic Substance Manufacturing federal obligations in FY2026

What the In-Vitro Diagnostic Mfg–FY2026 join is

NAICS 325413 and fiscal year 2026 meet here. $98,050,051.28 is the USAspending.gov obligation sum on the yearlyTrend row that carries both tags. It is not In-Vitro Diagnostic Substance Manufacturing's nationwide all-year total of $1,876,000,543.48, not every federal dollar coded to FY2026, and not an outlay register. The packet does not split reagents from kits from other in-vitro substances. 5,683 is an industry-extract action count: modifications and repeat awards add rows across years. Unique recipients are unpublished. This cell is not a lot-release log, a named-OEM roster, or a test-kit SKU catalog.

Open /industries/325413/ (NAICS 325413) for the industry table without this FY2026 filter, /fiscal-years/2026/ (FY2026 federal spending) for the year table without this NAICS filter, /industries/ (All industries) for every industry, and /ties/ (All spending ties) for the rest of the join list. Quote those hubs as parents, not as addends to $98,050,051.28. In-vitro diagnostic manufacturing is not residual chemical products (325998). Keep 325413 on FY2026.

FY2026 beside the In-Vitro Diagnostic Mfg longer book

USAspending labels NAICS 325413 as In-Vitro Diagnostic Substance Manufacturing. That code produced $98,050,051.28 when crossed with fiscal year 2026. The industry-wide 325413 hub does not require a FY2026 filter. The year hub does not require In-Vitro Diagnostic Mfg. Only this tie applies both filters. The packet does not split reagents from kits from other in-vitro substances. Reagents, kits, and other in-vitro substances stay inside one NAICS. This page will not invent that pie.

Correlation is not causation: FY2026 did not cause $98,050,051.28 by existing as a large or small budget year. The join is 325413 × FY2026 only. This cell is not a lot-release log, a named-OEM roster, or a test-kit SKU catalog. Do not invent contractors or award recipients to fill the gap. Campaign donations on FEC tables do not fund this USAspending cell; the datasets are separate. 5,683 industry-extract awards belong to 325413 across years, not to FY2026 as a SKU census.

5,683 industry-extract awards are not a FY2026 census

5,683 is the In-Vitro Diagnostic Substance Manufacturing award-record count published with the industry extract, not a count of FY2026 instruments. Dividing $98,050,051.28 by 5,683 would mix a one-year dollar total with a multi-year row count, so this page does not publish that ratio as a typical invoice. Unique recipients are unpublished. Modifications and multi-year vehicles can add lines without adding vendors. 5,683 industry-extract awards belong to 325413 across years, not to FY2026 as a SKU census. FY2026 figures can be incomplete for the current year, so even the dollar cell may still move.

A thick parent file makes a program split tempting; the packet still does not supply one. A thin parent file makes a named-facility story tempting; the packet still does not name facilities or contractors. 5.2% of $1,876,000,543.48 is the year share on this packet, not a performance score.

Obligations, not outlays

USAspending.gov records an obligation when the federal government commits funds on an award. $98,050,051.28 is that kind of sum for In-Vitro Diagnostic Substance Manufacturing in FY2026. Later deobligations, recoveries, or payment schedules can change what leaves the Treasury without this join rewriting itself into a cash register. Assistance and contract awards can share the same NAICS rollup; this packet does not split them. Net obligations can include downward adjustments. This page reports $98,050,051.28 as given.

Treat 5,683 as award records on the industry extract, not unique vendors and not a FY2026 headcount. Do not per-capita or per-recipient the dollar total; those denominators are unpublished. FEC contribution tables do not fund these awards. OEM names and lot numbers are unpublished. Obligations are not outlays.

How to cite In-Vitro Diagnostic Mfg in FY2026

Cite USAspending.gov: In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) obligated $98,050,051.28 in FY2026. Name In-Vitro Diagnostic Substance Manufacturing and FY2026 together. Keep the obligation word. If /industries/325413/ or /fiscal-years/2026/ has refreshed, prefer the live hub over this snapshot for current rows. The pair is not a lot-release log, a named-OEM roster, or a test-kit SKU catalog. 5.2% of $1,876,000,543.48 is the industry share on this packet, not a budget score. /industries/ lists other industries; /ties/ indexes other pairs.

Keep In-Vitro Diagnostic Substance Manufacturing, FY2026, $98,050,051.28, and the 5,683-record industry extract together without mixing clocks. Do not add those parents to this cell. Sharing a year with In-Vitro Diagnostic Mfg does not mean campaign donations funded these awards, and it does not convert obligations into outlays. This page reports one USAspending yearlyTrend join. In-vitro diagnostic manufacturing is not residual chemical products (325998). Keep 325413 on FY2026.

Limits of the 325413 × FY2026 snapshot

5,683 industry-extract awards belong to 325413 across years, not to FY2026 as a SKU census. In-vitro diagnostic manufacturing is not residual chemical products (325998). Keep 325413 on FY2026. A reader who quotes 5,683 as unique companies in FY2026 has left the packet. A reader who treats 5.2% as a hardship or success ranking has added a score the table does not carry. Prefer /industries/325413/ and /fiscal-years/2026/ if the live tables moved. OEM names and lot numbers are unpublished. Obligations are not outlays.

This snapshot holds $98,050,051.28 on the yearlyTrend row and 5,683 on the industry extract. /ties/ is the index, not an addend. Obligations are not outlays. Correlation is not causation. A reader who only quotes $98,050,051.28 without FY2026 and NAICS 325413 has dropped a join side.

Questions

How much In-Vitro Diagnostic Mfg spending is obligated in FY2026?

USAspending.gov lists $98,050,051.28 in In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) obligations for FY2026. That yearlyTrend amount is 5.2% of the industry's $1,876,000,543.48 extract-wide total. It is an obligation join, not an outlay and not every federal dollar in FY2026. Unique recipients are unpublished.

Is $98,050,051.28 the entire In-Vitro Diagnostic Mfg USAspending total?

No. NAICS 325413's extract-wide total is $1,876,000,543.48. FY2026 is 5.2% of that book. Other fiscal-year rows for the same industry are separate cells. Do not add /industries/325413/ into this join. 5,683 award records stay on the industry extract, not on this yearlyTrend row.

Is $98,050,051.28 cash already paid in FY2026?

No. Obligations are commitments recorded on USAspending.gov awards. Outlays — money that actually left the Treasury — are a different concept and are not this packet's headline. Treating $98,050,051.28 as checks already cleared in FY2026 confuses those terms. Prefer the live industry and year hubs if the tables moved.

Where is the live In-Vitro Diagnostic Mfg–FY2026 table?

/industries/325413/ is the industry parent and /fiscal-years/2026/ is the year parent. /industries/ covers every industry without the NAICS×year intersection as the headline. /ties/ lists other pairs. Those hubs are not addends. Keep both sides of the join when citing $98,050,051.28.